JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A5760 KRN 633

Summary: VEGFR inhibitor,ATP-competitive

insoluble in EtOH; insoluble in H2O; ≥13.75 mg/mL
A8313 RAF265

Target: Raf|VEGFR

Summary: Multiple intracellular kinases inhibitor

≥25.9 mg/mL
A8347 Pazopanib Hydrochloride

Summary: VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor

≥11.1 mg/mL
A8370 Axitinib (AG 013736)
1 Citation

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR1/ c-Kit inhibitor

insoluble in H2O; ≥19.3 mg/mL
A8418 Dovitinib Dilactic acid

Summary: FLT3 inhibitor

≥57.3 mg/mL
A8550 Telatinib (BAY 57-9352)

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR-2/-3,PDGFR-β and c-Kit inhibitor

insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL
A8555 Vandetanib (ZD6474)

Target: VEGFR|EGFR

Summary: VEGFR2/EGFR antagonist

insoluble in H2O; ≥11.88 mg/mL
B1305 SKLB1002

Summary: VEGFR2 inhibitor,potent and ATP-competitve
B2173 CP-673451

Target: PDGFR

Summary: PDGFRα/β inhibitor,potent and selective
B2303 Apatinib
1 Citation

Summary: VEGFR2 inhibitor, orally bioavailable, selective

≥49.4 mg/mL